Advice
Following an abbreviated submission.
Salmeterol 25 micrograms inhaler (Serevent Evohaler) is accepted for use in NHS Scotland for the regular symptomatic treatment of reversible airways obstruction in patients with asthma, including those with nocturnal asthma or chronic obstructive pulmonary disease. It may also be used for the prevention of exercise-induced asthma.
Where the use of this long-acting beta agonist by aerosol inhalation is appropriate, it offers a chlorofluorocarbon (CFC)-free option at no additional cost
Download detailed advice28KB (PDF)
Medicine details
- Medicine name:
- salmeterol 25 mcg inhaler (Serevent Evohaler)
- SMC ID:
- 292/06
- Indication:
- Reversible airways obstruction in patients with asthma
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 August 2006